Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Gild save search
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | $41.02 1.54% 0.0% 2.6M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
Published: 2023-12-04 (Crawled : 11:00) - prnewswire.com
IDYA | News | $39.025 3.82% 3.68% 490K
|
Health Technology
|
| O: -0.09%
H: 3.48%
C: 2.56%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.46%
H: 1.53%
C: 1.36%
ide397 trodelvy bladder cancer sciences collaboration study
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.2%
H: 1.8%
C: 1.62%
trodelvy breast symposium cancer
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
t-cell cancer blood therapy
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.56 -1.72% -1.75% 340K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.97 6.2% 2.21% 400K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.73 -1.06% -1.07% 720K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.28%
H: 0.04%
C: -1.1%
trodelvy chmp breast positive cancer
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 0.41%
H: 0.68%
C: 0.64%
PGEN | $1.4 1.45% 1.43% 510K
|
Health Technology
|
| O: 0.0%
H: 0.76%
C: -4.55%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 0.63%
H: 1.87%
C: -1.25%
ITOS | $11.0 1.95% 1.91% 300K
|
Health Technology
|
| O: -0.52%
H: 3.23%
C: -2.2%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.42%
H: 3.56%
C: 3.48%
cancer
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
trodelvy advantage breast cancer show
ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower...
Published: 2023-06-03 (Crawled : 00:20) - biospace.com/
RCUS 4 | $15.5 5.59% 0.0% 580K
|
Health Technology
| Email alert
Add to watchlist
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
| Email alert
Add to watchlist
cancer immunotherapy
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
Published: 2023-05-17 (Crawled : 14:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.22%
H: 1.12%
C: 0.85%
asco cancer pipeline care
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-02-03 (Crawled : 19:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 4.01%
H: 2.73%
C: -0.18%
trodelvy fda breast cancer her2 metastatic breast cancer
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.08%
H: 0.77%
C: -0.01%
awards breast health grants cancer
Global Precision Cancer Therapeutics Market Report 2022: Overview of Disease Epidemiology, Leading Product sales, Market Estimates and Forecasts, and Competitive Summary of Leading Providers
Published: 2022-12-30 (Crawled : 15:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: -0.74%
AZNCF | News | $138.73 -4.19% 3.7K
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: -0.25%
PFE | News A | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.08%
H: 0.21%
C: -0.1%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.01%
H: 0.08%
C: -0.95%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.16%
C: -0.47%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.04%
H: 0.21%
C: -0.25%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: 0.61%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: -0.32%
H: 2.91%
C: 2.75%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.46%
H: 0.38%
C: 0.01%
global disease report therapeutics cancer market
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published: 2022-12-20 (Crawled : 13:20) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -3.21%
H: 1.93%
C: 1.35%
acquire t-cell therapeutics therapy cancer
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $69.89 1.33% 0.0% 340K
|
Distribution Services
|
| O: -0.42%
H: 0.97%
C: -0.33%
PFE | News A | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
TRIB | $1.81 -3.87% 2.8K
|
Health Technology
|
| O: -1.56%
H: 1.58%
C: -1.75%
REPL | $6.41 -0.16% -0.16% 1.2M
|
Health Technology
|
| O: -0.25%
H: 5.25%
C: 4.17%
MYGN | $18.595 0.57% 0.56% 510K
|
Health Technology
|
| O: -0.67%
H: 1.39%
C: -2.69%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
APM | $5.37 -5.12% -5.6% 35K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
risk breast genetic cancer study
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Published: 2022-10-20 (Crawled : 14:20) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.05%
H: 0.57%
C: 0.0%
blood license agreement platform cancer
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.05%
H: 2.4%
C: 1.82%
trodelvy fda breast application license review cancer her2- her2 metastatic breast cancer
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Published: 2022-10-06 (Crawled : 13:00) - prnewswire.com
ZLAB | $15.13 0.93% 0.93% 470K
|
Health Technology
|
| O: 0.35%
H: 1.48%
C: -4.65%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.04%
H: 0.67%
C: -0.47%
PDSB | $3.2 7.02% 6.56% 990K
|
Health Technology
|
| O: -0.55%
H: 6.11%
C: -0.56%
ILMN | $124.41 3.46% 3.34% 1.3M
|
Health Technology
|
| O: -0.88%
H: 1.39%
C: -1.79%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.86%
H: 0.72%
C: 0.09%
treatment global expected cancer market
Susan G. Komen® MORE THAN PINK Walk Raises Money To Improve Outcomes For Breast Cancer Patients
Published: 2022-09-22 (Crawled : 15:00) - prnewswire.com
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.24%
H: 1.52%
C: 0.66%
komen cancer
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
Published: 2022-08-15 (Crawled : 16:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 1.41%
H: 3.83%
C: 3.7%
cs-02 trodelvy cancer study her2- her2 metastatic breast cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.